Characteristics | All Patients, n = 106 | CC16 ≤ 33 ng/ml, n = 53 | CC16 > 33 ng/ml, n = 53 | p |
---|---|---|---|---|
Age, yrs | 55.4 ± 12.7 | 51.4 ± 12.5 | 59.4 ± 11.6 | < 0.01 |
Female sex | 94 (89) | 47 (89) | 47 (89) | ns |
Duration of SSc, yrs | 13.2 ± 12.6 | 11.5 ± 11 | 14.9 ± 13.9 | ns |
dcSSc | 37 (35) | 23 (43) | 14 (26) | ns |
mRSS | 8.6 ± 7 | 7.5 ± 5.5 | 9.6 ± 8.2 | ns |
HAQ | 0.77 ± 0.75 | 0.73 ± 0.7 | 0.8 ± 0.8 | ns |
ILD | 56 (52.8) | 27 (51) | 29 (55) | ns |
FVC | 96 ± 21 | 95 ± 22 | 96 ± 21 | ns |
TLC | 96 ± 17 | 98 ± 16 | 94 ± 17 | ns |
DLCO | 62 ± 16 | 65 ± 16 | 59 ± 16 | ns |
Systolic PAP, mmHg* | 34 ± 8 | 33 ± 6 | 36 ± 9 | ns |
Current smokers | 24 (22.6) | 15 (28) | 9 (17) | 0.54 |
Serum creatinine, µmol/l | 82 ± 18 | 76 ± 12 | 87 ± 22 | 0.01 |
ACA | 48 (45) | 21 (39) | 27 (51) | 0.33 |
Anti-topo I | 29 (27) | 17 (32) | 12 (23) | 0.38 |
Immunosuppressive therapy | 18 (17) | 12 (23) | 6 (11) | 0.19 |
↵* Assessed by echocardiography. CC16: Clara cell 16 kDa; SSc: systemic sclerosis; HAQ: Health Assessment Questionnaire; ILD: interstitial lung disease; FVC: forced vital capacity; TLC: total lung capacity; PAP: pulmonary arterial pressure; dcSSc: diffuse cutaneous SSc; mRSS: modified Rodnan skin score; ACA: anticentromere antibodies; anti-topo I: antitopoisomerase I antibodies; ns: nonsignificant.